HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

CUSIP: 40637H109

Q4 2020 13F Holders as of 31 Dec 2020

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
136,300,724
Share change
+2,109,659
Total reported value
$5,821,984,170
Put/Call ratio
31%
Price per share
$42.71
Number of holders
335
Value change
+$126,547,922
Number of buys
189
Number of sells
127

Sponsored

Quarterly Holders Quick Answers

What is CUSIP 40637H109?
CUSIP 40637H109 identifies HALO - HALOZYME THERAPEUTICS, INC. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2020

As of 31 Dec 2020, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 335 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 136,300,724 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, Artisan Partners Limited Partnership, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, STATE STREET CORP, Invesco Ltd., JPMORGAN CHASE & CO, Bellevue Group AG, SNYDER CAPITAL MANAGEMENT L P, and GOLDMAN SACHS GROUP INC. This page lists 335 institutional shareholders reporting positions in this security for the Q4 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q4 2020 vs Q3 2020 Across Filers

Q3 2020 holders
262
Q4 2020 holders
335
Holder diff
73
Investor Q3 2020 Shares Q4 2020 Shares Share Diff Share Chg % Q3 2020 Value $ Q4 2020 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.